Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human PLAU Antibodies:
anti-Mouse (Murine) PLAU Antibodies:
anti-Rat (Rattus) PLAU Antibodies:
Go to our pre-filtered search.
Human Polyclonal PLAU Primary Antibody for FACS, IHC (p) - ABIN1882148
Strausberg, Feingold, Grouse, Derge, Klausner, Collins, Wagner, Shenmen, Schuler, Altschul, Zeeberg, Buetow, Schaefer, Bhat, Hopkins, Jordan, Moore, Max, Wang, Hsieh, Diatchenko, Marusina, Farmer et al.: Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. ... in Proceedings of the National Academy of Sciences of the United States of America 2002
Show all 8 Pubmed References
Mouse (Murine) Monoclonal PLAU Primary Antibody for ELISA (Capture), ELISA (Detection) - ABIN491262
Botkjaer, Deryugina, Dupont, Gårdsvoll, Bekes, Thuesen, Chen, Chen, Ploug, Quigley, Andreasen: Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism. in Molecular cancer research : MCR 2012
Show all 3 Pubmed References
Human Monoclonal PLAU Primary Antibody for ELISA (Capture), ELISA (Detection) - ABIN491259
Florova, Azghani, Karandashova, Schaefer, Koenig, Stewart-Evans, Declerck, Idell, Komissarov: Targeting of plasminogen activator inhibitor 1 improves fibrinolytic therapy for tetracycline-induced pleural injury in rabbits. in American journal of respiratory cell and molecular biology 2015
Show all 2 Pubmed References
Human Polyclonal PLAU Primary Antibody for EIA, IHC (fro) - ABIN191518
Coy, Jiménez-Movilla, García-Vázquez, Mondéjar, Grullón, Romar: Oocytes use the plasminogen-plasmin system to remove supernumerary spermatozoa. in Human reproduction (Oxford, England) 2012
Human Polyclonal PLAU Primary Antibody for ELISA, WB - ABIN250818
Morgan, Hill: Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity. in Cancer cell international 2005
Mouse (Murine) Polyclonal PLAU Primary Antibody for ELISA (Detection), IHC (fro) - ABIN491326
Zhang, Kernan, Thomas, Collins, Song, Li, Zhu, Leboeuf, Eddy: A novel signaling pathway: fibroblast nicotinic receptor alpha1 binds urokinase and promotes renal fibrosis. in The Journal of biological chemistry 2009
Human Polyclonal PLAU Primary Antibody for ELISA, WB - ABIN2477037
Woo, OBrien, Gillies, Etheridge: Mechanical and radiation isocenter coincidence: an experience in linear accelerator alignment. in Medical physics 1992
Show all 2 Pubmed References
Human Polyclonal PLAU Primary Antibody for IHC (p), IHC - ABIN439170
Lee, Oh, Park, Na, Gil, Yang, Lee, Hong: Urokinase, urokinase receptor, and plasminogen activator inhibitor-1 expression on podocytes in immunoglobulin A glomerulonephritis. in The Korean journal of internal medicine 2014
Results provide evidence that uPA (show PRAP1 Antibodies) and IGF1R (show IGF1R Antibodies) directly interact with uPAR (show PLAUR Antibodies) enhancing malignant potential of triple-negative breast cancer.
suggest that the low endogenous levels of uPA (show PRAP1 Antibodies) in blood are actively regulated, and that the regulatory mechanisms are disrupted in QPD in a megakaryocyte-specific manner
an intricate link between caveolin-1 (show CAV1 Antibodies) and Src kinase (show CSK Antibodies)-mediated cell signaling and alveolar epithelial cell apoptosis due to loss of SP-C (show SFTPC Antibodies) expression through p53 (show TP53 Antibodies) and uPA (show PRAP1 Antibodies) system-mediated cross-talk, is reported.
results show that the uPA (show PRAP1 Antibodies)/uPAR (show PLAUR Antibodies)/LRP1 (show LRP1 Antibodies) system is a potential target for the development of therapeutic strategies to promote axonal recovery following a CNS injury
The present research concluded that aspirin suppressed prostate cancer cell invasion by reducing MMP-9 (show MMP9 Antibodies) activity and uPA (show PRAP1 Antibodies) expression through decreasing of IKK-beta (show IKBKB Antibodies)-mediated NF-kappaB (show NFKB1 Antibodies) activation, indicating that the ability of aspirin to inhibit cell invasion might be useful in the chemoprevention of metastatic prostate cancer.
These studies identify uPA (show PRAP1 Antibodies)-dependent de-repression of vegfr1 (show FLT1 Antibodies) and vegfr2 (show KDR Antibodies) gene transcription through binding to HHEX/PRH (show HHEX Antibodies) as a novel mechanism by which uPA (show PRAP1 Antibodies) mediates the pro-angiogenic effects of VEGF (show VEGFA Antibodies) and identifies a potential new target for control of pathologic angiogenesis.
We concluded that overexpression of MMP-3 (show MMP3 Antibodies) and uPA (show PRAP1 Antibodies), altogether with diminished expression of PAI-1 (show SERPINE1 Antibodies) from metastatic tumors, might be a crucial step towards metastasis in ductal breast cancer.
The up-regulation of uPA (show PRAP1 Antibodies) mRNAs was correlated with high-risk clinicopathological features, including extrathyroid invasion, loss of cellular polarity/cohesiveness, and the BRAF (show BRAF Antibodies)(V600E) mutation.
In contrast to platelet-derived growth factor, all urokinase isoforms induced secretion of MMP-9 (show MMP9 Antibodies) by mesenchymal stromal cells.
Transplantation of uPA (show PRAP1 Antibodies) gene modified mesenchymal stem cells suppressed liver fibrosis and ameliorated liver function and may be a new approach to treating liver fibrosis
an intricate link between caveolin-1 (show CAV1 Antibodies) and Src kinase (show CSK Antibodies)-mediated cell signaling and alveolar epithelial cell apoptosis due to loss of SP-C (show SFTPC Antibodies) expression through p53 (show TP53 Antibodies) and uPA system-mediated cross-talk, is reported.
These studies identify uPA-dependent de-repression of vegfr1 (show FLT1 Antibodies) and vegfr2 (show KDR Antibodies) gene transcription through binding to HHEX/PRH (show HHEX Antibodies) as a novel mechanism by which uPA mediates the pro-angiogenic effects of VEGF (show VEGFA Antibodies) and identifies a potential new target for control of pathologic angiogenesis.
Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.
GM-CSF (show CSF2 Antibodies) and uPA are required for Porphyromonas gingivalis-induced alveolar bone loss in a mouse periodontitis model.
Plau deficiency does not worsen controlled cortical impact-induced brain pathology or epileptogenesis caused by TBI.
we have firstly shown a fundamental mechanism of urokinase system(uPa and uPAR (show PLAUR Antibodies))-dependent regulation of the trajectory of growth and branching of blood vessels in early embryogenesis and in adults during the repair/regeneration of tissues.
Pharmacological inhibition of either uPA or selected MMPs decreased atherosclerosis in transgenic uPA mice.
Study shows that the competitive expression or activity of tPA (show PLAT Antibodies) and/or PAI-1 (show SERPINE1 Antibodies), rather than an altered uPA expression, determines the plasmin (show PLG Antibodies)-mediated Abeta (show APP Antibodies) proteolysis in brains affected by Alzheimer's disease
Porphyromonas gingivalis-derived RgpA-Kgp complex activates the macrophage uPA.
beta-elemene downregulates expression of uPA, uPAR (show PLAUR Antibodies), MMP-2 (show MMP2 Antibodies), and MMP-9 (show MMP9 Antibodies) in a murine intraocular melanoma model
uPA-mediated arterial constriction is a vasomotor process that is mediated by uPA catalytic activity, not by the NH(2)-terminal domains.
Data show that urokinase-type plasminogen activator (uPA) is only expressed in the cumulus cells of immature and in vitro matured cumulus-oocyte complexes (COCs), while uPA receptor (uPAR (show PLAUR Antibodies)) and plasminogen activator inhibitor-1 (PAI-1 (show SERPINE1 Antibodies)) are expressed in both the cumulus cells and the immature and in vitro matured oocytes.
uPA/uPAR (show PLAUR Antibodies) binding is involved in signaling pathways that activate transcription factors that regulate the synthesis of molecules concerned with the arrangement of a particular oviductal microenvironment.
These data indicated that E. coli LPS (show IRF6 Antibodies) led to an increase in u-PA activity and RNA expression of u-PA and u-PAR (show PLAUR Antibodies) in BME-UV1 cells, thus strengthening the role of the PA system during pathological processes.
The plasminogen/plasminogen (show PLG Antibodies) activator/plasmin (show PLG Antibodies) system is activated during gamete interaction and regulates the sperm entry into the oocyte.
stage-dependent regulation of granulosa cell PA and SerpinE2 (show SERPINE2 Antibodies) production, consistent with a role in extracellular matrix remodeling during follicle growth.
This gene encodes a serine protease involved in degradation of the extracellular matrix and possibly tumor cell migration and proliferation. A specific polymorphism in this gene may be associated with late-onset Alzheimer's disease and also with decreased affinity for fibrin-binding. This protein converts plasminogen to plasmin by specific cleavage of an Arg-Val bond in plasminogen. Plasmin in turn cleaves this protein at a Lys-Ile bond to form a two-chain derivative in which a single disulfide bond connects the amino-terminal A-chain to the catalytically active, carboxy-terminal B-chain. This two-chain derivative is also called HMW-uPA (high molecular weight uPA). HMW-uPA can be further processed into LMW-uPA (low molecular weight uPA) by cleavage of chain A into a short chain A (A1) and an amino-terminal fragment. LMW-uPA is proteolytically active but does not bind to the uPA receptor. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.
urokinase-type plasminogen activator
, U-plasminogen activator
, plasminogen activator, urokinase
, plasminogen activator, urinary
, Urinary plasminogen activator, urokinase
, urokinase plasminogen activator preproprotein